Kestrel Therapeutics received FDA investigational new drug clearance for KST‑6051, an oral pan‑KRAS inhibitor aimed at KRAS‑driven cancers, enabling a first‑in‑human phase I (FALCON) trial slated to begin by the end of the quarter. The IND greenlight allows dose‑escalation in advanced solid tumors harboring KRAS mutations. KRAS mutations are among the most common oncogenic drivers across tumor types; a pan‑KRAS small molecule seeks to inhibit multiple oncogenic variants. The IND nod advances Kestrel into clinical development amid growing interest in targeting historically ‘undruggable’ RAS biology.